Domain and Rusnano sign $760m US-Russian healthcare investment tie-up
This article was originally published in Scrip
Domain Associates, one of the largest US venture capital firms operating in the healthcare sector, and Rusnano, the Russian state-owned investor in high-tech industries, have come together in an investment partnership focused on US innovation and Russian manufacturing. The firms have agreed to invest about $760 million from their venture capital funds in about 20 US-based healthcare technology companies and in building a pharmaceutical and medical device manufacturing facility in Russia.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.